| pubmed-article:10218901 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C1704256 | lld:lifeskim |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C0035696 | lld:lifeskim |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:10218901 | lifeskim:mentions | umls-concept:C0024485 | lld:lifeskim |
| pubmed-article:10218901 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10218901 | pubmed:dateCreated | 1999-6-7 | lld:pubmed |
| pubmed-article:10218901 | pubmed:abstractText | Eight relapsing-remitting multiple sclerosis (MS) patients were tested for the level of transforming growth factor beta1 (TGFbeta1) mRNA in peripheral blood mononuclear cells every 15 days for 6 months. Disease activity was evaluated every 4 weeks by magnetic resonance imaging (MRI) and neurological examination. An inverse correlation was found between the level of TGFbeta1 mRNA and MRI disease activity. The level of TGFbeta1 mRNA predicted the presence of disease activity in the scans performed 2-4 weeks later with high sensitivity (88%) and specificity (87.5%) suggesting that TGFbeta1 mRNA quantification could be an indicator of disease activity in MS. | lld:pubmed |
| pubmed-article:10218901 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10218901 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10218901 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10218901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10218901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10218901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10218901 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10218901 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10218901 | pubmed:issn | 0304-3940 | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:MutaniRR | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:BertolottoAA | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:BradacG BGB | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:CapobiancoMM | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:BerguiMM | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:ManzardoEE | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:MalucchiSS | lld:pubmed |
| pubmed-article:10218901 | pubmed:author | pubmed-author:AudanoLL | lld:pubmed |
| pubmed-article:10218901 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10218901 | pubmed:day | 19 | lld:pubmed |
| pubmed-article:10218901 | pubmed:volume | 263 | lld:pubmed |
| pubmed-article:10218901 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10218901 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10218901 | pubmed:pagination | 21-4 | lld:pubmed |
| pubmed-article:10218901 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:meshHeading | pubmed-meshheading:10218901... | lld:pubmed |
| pubmed-article:10218901 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10218901 | pubmed:articleTitle | Transforming growth factor beta1 (TGFbeta1) mRNA level correlates with magnetic resonance imaging disease activity in multiple sclerosis patients. | lld:pubmed |
| pubmed-article:10218901 | pubmed:affiliation | Multiple Sclerosis Center, Divisione Universitaria di Neurologia, Ospedale S. Luigi, Orbassano (TO), Italy. csmberto@yahoo.com | lld:pubmed |
| pubmed-article:10218901 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10218901 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10218901 | lld:pubmed |
